Get the Stockscreener App
64.77
1.16%
0.74
Arcellx Inc stock is traded at $64.77, with a volume of 504.83K.
It is up +1.16% in the last 24 hours and up +1.33% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$64.03
Open:
$63.81
24h Volume:
504.83K
Relative Volume:
0.68
Market Cap:
$3.65B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-21.66
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+1.49%
1M Performance:
+1.33%
6M Performance:
-18.03%
1Y Performance:
+20.70%
1-Day Range:
$63.28
$64.90
1-Week Range:
$60.92
$65.33
52-Week Range:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
64.77 | 3.65B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Citi initiates Arcellx stock with buy rating on cell therapy potential - Investing.com
Citi initiates Arcellx stock with buy rating on cell therapy potential By Investing.com - Investing.com South Africa
Cancer Cell Market Exclusive Report with Detailed Study Analysis | Abbott Laboratories, Cellectis, Arcellx, GE - newstrail.com
Citigroup Initiates Arcellx at Buy With $110 Price Target - MarketScreener
Arcellx initiated with a Buy at Citi - TipRanks
Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus
Aileen Fernandes | People on The MoveSan Francisco Business Times - The Business Journals
Aileen Fernandes - The Business Journals
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment - TipRanks
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential - TipRanks
ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus
Arcellx stock maintains buy rating at H.C. Wainwright on launch plans - Investing.com
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating - TipRanks
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning - TipRanks
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy - TipRanks
Rhumbline Advisers Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Transcript : Arcellx, Inc.Special Call - MarketScreener
(ACLX) Technical Data - news.stocktradersdaily.com
Arcellx’s SWOT analysis: CAR-T pioneer’s stock poised for myeloma market shake-up - Investing.com
arcellx director Kavita Patel sells shares worth $101,040 By Investing.com - Investing.com Nigeria
arcellx director Kavita Patel sells shares worth $101,040 - Investing.com
Brokers Set Expectations for Arcellx FY2026 Earnings - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Two Sigma Investments LP - Defense World
FY2026 EPS Estimates for Arcellx Lifted by Leerink Partnrs - Defense World
Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World
Kalkine: Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media
Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Holds Annual Stockholders Meeting - TipRanks
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister
Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga
Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey
BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcellx Inc Stock (ACLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Kavita | Director |
Jun 10 '25 |
Sale |
67.36 |
1,500 |
101,040 |
0 |
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):